GlassScriptPhysician profile
James Aldridge
NPI 1619608916
$2,430.25
in general payments reported to CMS, 2019-2025
16 companies · $966 in 2025
The $966 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $260 · 2023: $367 · 2024: $837 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.70 | 2023-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $258.51 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $227.89 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.62 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Scientific Affairs, LLC | $220.35 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $170.00 | 2022-2025 | |
| 3b Medical, INC. | $165.63 | 2024 | Luna |
| Novo Nordisk INC | $142.49 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $134.88 | 2025 | Arexvy, Shingrix |
| Calliditas Therapeutics US INC. | $125.01 | 2023 | Tarpeyo |
| Vifor Pharma, INC. | $122.23 | 2022 | |
| Merck Sharp & Dohme LLC | $111.65 | 2023 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $57.44 | 2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $31.92 | 2024-2025 | Voquezna |
| Sandoz INC. | $22.18 | 2024 | Hyrimoz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.75 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Aldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.